AVENTUS simplifies PE. Redefining thrombectomy with streamlined procedures, precise clot targeting, and best-in-class safety and efficacy.
AVENTUS simplifies PE. Redefining thrombectomy with streamlined procedures, precise clot targeting, and best-in-class safety and efficacy.
- Clinically proven. Streamlined for efficiency. Designed for precision.
- Built-in dilator + 5F navigation catheter
- Integrated clot management system
- Revolutionary simplicity
- Directional aspiration
- TrueClot™ sensing
AVENTUS simplifies PE. Redefining thrombectomy with streamlined procedures, precise clot targeting, and best-in-class safety and efficacy.
- Clinically proven. Streamlined for efficiency. Designed for precision.
- Built-in dilator + 5F navigation catheter
- Integrated clot management system
- Revolutionary simplicity
- Directional aspiration
- TrueClot™ sensing
The Serious Threat of Venous Thromboembolism (VTE)
leading cause of vascular death in the world1
0
rd
patients in the U.S. affected each year2
9
K
mortality for pulmonary embolism within the first month of diagnosis3–4
0
%
of patients with deep vein thrombosis will eventually have a pulmonary embolism (PE)5
>
0
%
Latest News
Inquis Medical’s AVENTUS Thrombectomy System Receives FDA 510(k) Clearance for Treatment of Pulmonary Embolism
June 16, 2025 09:30 ET – Pioneering device combines precision clot removal with autologous blood reinfusion to address unmet needs
Trial Finds Inquis Medical’s AVENTUS Thrombectomy System Safe and Effective for Patients with Pulmonary Embolism
May 02, 2025 11:50 ET – Results of AVENTUS IDE Trial presented at SCAI Scientific Sessions Inquis Medical, a leading
Inquis Medical Completes Enrollment in U.S. Pivotal IDE Trial of the Aventus Thrombectomy System Designed to Treat Patients with Pulmonary Embolism
MENLO PARK, Calif. — January 13, 2025 – Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced